Last reviewed · How we verify
Angiotensin-Converting Enzyme Inhibitors — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Angiotensin-Converting Enzyme Inhibitors (Angiotensin-Converting Enzyme Inhibitors) — Boehringer Ingelheim.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Angiotensin-Converting Enzyme Inhibitors TARGET | Angiotensin-Converting Enzyme Inhibitors | Boehringer Ingelheim | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Angiotensin-Converting Enzyme Inhibitors CI watch — RSS
- Angiotensin-Converting Enzyme Inhibitors CI watch — Atom
- Angiotensin-Converting Enzyme Inhibitors CI watch — JSON
- Angiotensin-Converting Enzyme Inhibitors alone — RSS
Cite this brief
Drug Landscape (2026). Angiotensin-Converting Enzyme Inhibitors — Competitive Intelligence Brief. https://druglandscape.com/ci/angiotensin-converting-enzyme-inhibitors. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab